thumb
November 22, 2021

Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa).

thumb
November 17, 2021

Update on Regulatory Review of Aducanumab in the European Union

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today an update on the ongoing review of the Marketing Authorization Application for aducanumab 100 mg/mL concentrate solution for infusion for the treatment of Alzheimer’s

thumb
November 16, 2021

The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis

VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s leadership in MS oral therapies Phase 3 data have demonstrated that treatment with VUMERITY results in low discontinuation rates

thumb
November 15, 2021

Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) announced today that Alfred “Al” W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company effective December 31, 2021. A 23-year veteran of Biogen, Dr.

thumb
November 15, 2021

Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year

Biogen earns top ESG leadership scores on areas including Innovation Management and Climate Strategy, highlighting efforts to address urgent and long-term challenges facing humanity In 2021, Biogen notably bolstered its longstanding corporate responsibility leadership actions by implementing bold

thumb
November 11, 2021

New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease

In a pre-specified analysis, ADUHELM significantly lowered plasma p-tau181, a biomarker of the hallmark tau tangles in Alzheimer’s disease, in both Phase 3 trials in a dose- and time-dependent manner vs. placebo Change in plasma p-tau181 was significantly correlated with change in amyloid beta

thumb
November 11, 2021

Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Nov.11, 2021 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced a presentation about exploring the use of plasma-based biomarkers

thumb
November 11, 2021

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference

Consistency of Efficacy Assessments Evaluated Across Various Statistical Methods TOKYO and CAMBRIDGE, Mass., Nov.11, 2021 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos,

thumb
November 10, 2021

Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2B Study Core and Open-Label Extension Across Five Years at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass, Nov. 10, 2021 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today results of new clinical, biomarker and safety assessments of

thumb
November 3, 2021

Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Late breaker will show ADUHELM™ effect on plasma pTau181 reduction, and its correlation with amyloid beta and slowing cognitive and functional decline. Additional phase 3b late breaker data will shed light on clinical decline and amyloid beta plaque levels after patients stopped treatment.